Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biohaven Ltd (NY: BHVN )

50.88 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biohaven Ltd

< Previous 1 2 3 4 5 6 7 8 Next >
Why Immunic Shares Jumped By Around 57%; Here Are 73 Biggest Movers From Yesterday
Gainers Applied DNA Sciences, Inc. (NASDAQ: APDN) shares climbed 71% to close at $2.12 on Monday after the company announced it has received its largest single purchase order for LinearDNA™ valued... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 
Via Benzinga
Recap: Biohaven Pharma Hldgs Q2 Earnings
Biohaven Pharma Hldgs (NYSE:BHVN) reported its Q2 earnings results on Friday, August 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Coinbase Global And 3 Other Stocks Insiders Are Buying
Although US stocks closed lower on Thursday, there were a few notable insider trades. 
Via Benzinga
Biohaven Ltd. Surges 7.6%: Is This An Indication Of Further Gains?
Biohaven Ltd. shares ended the last trading session 7.6% higher at $13.18. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares... 
Via Talk Markets
Pinterest, Perion Network And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Why WISeKey International Is Trading Higher By Over 20%; Here Are 29 Stocks Moving Premarket
Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 89.4% to $0.2655 in pre-market trading. Statera Biopharma was recently granted European patent number EP3206708 titled "Methods And Compositions For... 
Via Benzinga
Why Nauticus Robotics Shares Are Trading Higher By 96%; Here Are 67 Biggest Movers From Yesterday
Gainers Chardan NexTech Acquisition 2 Corp. (NASDAQ: CNTQ) shares surged 102.6% to close at $21.54 on Wednesday. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 44 companies hit new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Avenue Therapeutics (NASDAQ:ATXI) shares moved upwards by 37.7% to $15.85 during Tuesday's pre-market session. The company's market cap stands at $23.3 million. 
Via Benzinga
Pfizer Completes Acquisition of Biohaven Pharmaceuticals
From Pfizer Inc.
Via Business Wire
IPO Scorcher Amylyx Wins FDA Approval In ALS Treatment, Ending A Long Battle
The drug has faced two advisory committees and a delayed review date. 
Via Investor's Business Daily
Biohaven's ALS Drug Fails To Meet Study Endpoint, Second Therapy To Fail Trials In Recent Months
Biohaven Pharmaceutical Holding Company Ltd (NASDAQ: BHVN) announced results from a focused analysis of verdiperstat in the HEALEY ALS Platform Trial in amyotrophic lateral sclerosis (ALS).  
Via Benzinga
Top-Notch Biohaven Pharmaceutical Stock Trips As ALS Drug Flops In Key Test
Patients didn't show any improvements in a study meant to test multiple drugs. 
Via Investor's Business Daily
Shares of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Rise Above Previous 52-Week High
Via Investor Brand Network
Shares of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Exceed 52-Week High
Via Investor Brand Network
Stocks That Hit 52-Week Highs On Friday
  On Friday, 5 companies hit new 52-week highs. 
Via Benzinga
Watch for Continued Gains in Shares of Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
Via Investor Brand Network
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
Is Viatris Inc. a Contrarian Dividend Option for Your Portfolio?
Does kicking against market trends make you even more excited about investing? If so, you may want to consider drugmaker Viatris Inc. (NASDAQ: VTRS), which produces products that treat diabetes,... 
Via MarketBeat
Biohaven Pharmaceutical's Return On Capital Employed Overview
Benzinga Pro data, Biohaven Pharmaceutical (NYSE:BHVN) reported Q2 sales of $215.08 million. Earnings fell to a loss of $441.88 million, resulting in a 278.01% decrease from last quarter. 
Via Benzinga
$5.6 Million Bet On This Healthcare Stock? 3 Stocks Insiders Are Buying
Although US stocks closed sharply lower on Monday, there were a few notable insider trades. 
Via Benzinga
Freedom Biosciences Gets $10.5M In Seed Financing For Psychedelics Research, This Is What We Know
Freedom Biosciences achieved a major $10.5 million in a seed financing round in which MBX Capital, PsyMed Ventures, Village Global and The Yale Startup, among others, participated. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2022
Upgrades 
Via Benzinga
Why These Pfizer Analysts Like The Global Blood Therapeutics Deal
Pfizer Inc. (NYSE: PFE) shares were trading lower Monday after the drugmaker announced a $5.4-billion bid to acquire blood disorder drugmaker Global Blood Therapeutics Inc (NASDAQ: GBT). 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022
  
Via Benzinga
Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion
Shares of Pfizer's rumored takeover target have rocketed for two days running. 
Via Investor's Business Daily
The 3 Best Market Sectors for the Second Half of 2022
Compelling themes will drive a recovery in some sectors over the second half of 2022. The following are the best market sectors to buy into. 
Via InvestorPlace
Which Coronavirus Stock Could Fetch Higher Returns?
This article will compare Pfizer, Moderna, and Novavax to see which of these coronavirus stocks will yield the highest returns. 
Via InvestorPlace
Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’S VT1021 in GBM AGILE Trial
From Global Coalition for Adaptive Research
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.